{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:24:59Z","timestamp":1784291099028,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10147-025-02869-0","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T03:14:27Z","timestamp":1756437267000},"page":"2223-2235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative neurological safety of novel hormonal therapies in advanced prostate cancer: a Bayesian network meta-analysis of randomized trials"],"prefix":"10.1007","volume":"30","author":[{"given":"Ganesh","family":"Bushi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aftab","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urooj","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqa","family":"Sayyed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Shabil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"6","key":"2869_CR1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","volume":"4","author":"G Gandaglia","year":"2021","unstructured":"Gandaglia G et al (2021) Epidemiology and prevention of prostate cancer. Eur Urol Oncol 4(6):877\u2013892","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"2869_CR2","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3390\/cancers14071792","volume":"14","author":"C Cattrini","year":"2022","unstructured":"Cattrini C et al (2022) Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers 14(7):1792","journal-title":"Cancers"},{"issue":"18","key":"2869_CR3","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.3390\/cancers16183187","volume":"16","author":"W-A Kwon","year":"2024","unstructured":"Kwon W-A, Song YS, Lee M-K (2024) Strategic advances in combination therapy for metastatic castration-sensitive prostate cancer: current insights and future perspectives. Cancers (Basel) 16(18):3187","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2869_CR4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2023.05.009","volume":"85","author":"E Colomba","year":"2024","unstructured":"Colomba E et al (2024) A randomized, open-label, cross-over phase 2 trial of darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer: patient preference and cognitive function in ODENZA. Eur Urol 85(3):274\u2013282","journal-title":"Eur Urol"},{"issue":"8","key":"2869_CR5","first-page":"561","volume":"32","author":"M-F Cui","year":"2024","unstructured":"Cui M-F et al (2024) Risks associated with cognitive function and management strategies in the clinical use of ADT: a systematic review from clinical and preclinical studies. Support Care Cancer 32(8):561","journal-title":"Support Care Cancer"},{"key":"2869_CR6","doi-asserted-by":"crossref","unstructured":"Dhillon S, Antolin AA, Jones AM (2024) The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with non-steroidal androgen antagonists in The United Kingdom. medRxiv, 2024.07. 09.24309949","DOI":"10.1101\/2024.07.09.24309949"},{"issue":"2","key":"2869_CR7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/uro2.22","volume":"1","author":"S Han","year":"2023","unstructured":"Han S et al (2023) Consensus on safety management of novel hormonal therapy for advanced prostate cancer. UroPrecision 1(2):53\u201371","journal-title":"UroPrecision"},{"issue":"4","key":"2869_CR8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000515014","volume":"44","author":"R Sope\u00f1a Sutil","year":"2021","unstructured":"Sope\u00f1a Sutil R et al (2021) Seizures and neuropsychiatric toxicity in patients with non-metastatic CRPC treated with new antiandrogens: systematic review and meta-analysis. Oncol Res Treat 44(4):154\u2013163","journal-title":"Oncol Res Treat"},{"key":"2869_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104273","author":"L Zhen","year":"2024","unstructured":"Zhen L et al (2024) A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: how to choose drugs appropriately? Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104273","journal-title":"Crit Rev Oncol Hematol"},{"key":"2869_CR10","doi-asserted-by":"crossref","first-page":"102251","DOI":"10.1016\/j.clgc.2024.102251","volume":"23","author":"A Matsukawa","year":"2024","unstructured":"Matsukawa A et al (2024) Central nervous system toxicity in prostate cancer patients treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. Clin Genitourin Cancer 23:102251","journal-title":"Clin Genitourin Cancer"},{"key":"2869_CR11","doi-asserted-by":"crossref","first-page":"1148021","DOI":"10.3389\/fphar.2023.1148021","volume":"14","author":"T Jian","year":"2023","unstructured":"Jian T et al (2023) Combination therapy for high-volume versus low-volume metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Front Pharmacol 14:1148021","journal-title":"Front Pharmacol"},{"issue":"6","key":"2869_CR12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.medcle.2016.10.003","volume":"147","author":"B Hutton","year":"2016","unstructured":"Hutton B, Catala-Lopez F, Moher D (2016) The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA. Medicina Cl\u00ednica (English Edition) 147(6):262\u2013266","journal-title":"Medicina Cl\u00ednica (English Edition)"},{"issue":"10","key":"2869_CR13","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1097\/JS9.0000000000001480","volume":"110","author":"T Alrahbeni","year":"2024","unstructured":"Alrahbeni T et al (2024) Surgical interventions for intractable migraine: a systematic review and meta-analysis. Int J Surg 110(10):6306\u20136313","journal-title":"Int J Surg"},{"issue":"7","key":"2869_CR14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101666","volume":"48","author":"M Shabil","year":"2023","unstructured":"Shabil M et al (2023) Cardiovascular manifestation in tuberculosis cases: a systematic review and meta-analysis. Curr Probl Cardiol 48(7):101666","journal-title":"Curr Probl Cardiol"},{"issue":"13","key":"2869_CR15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197","journal-title":"N Engl J Med"},{"issue":"11","key":"2869_CR16","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K et al (2020) Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 383(11):1040\u20131049","journal-title":"N Engl J Med"},{"issue":"15","key":"2869_CR17","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ et al (2022) Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 40(15):1616\u20131622","journal-title":"J Clin Oncol"},{"issue":"3","key":"2869_CR18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","volume":"78","author":"AJ Armstrong","year":"2020","unstructured":"Armstrong AJ et al (2020) Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol 78(3):347\u2013357","journal-title":"Eur Urol"},{"issue":"23","key":"2869_CR19","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN et al (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382(23):2197\u20132206","journal-title":"N Engl J Med"},{"issue":"1","key":"2869_CR20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR et al (2021) Apalutamide and overall survival in prostate cancer. Eur Urol 79(1):150\u2013158","journal-title":"Eur Urol"},{"issue":"20","key":"2869_CR21","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39(20):2294\u20132303","journal-title":"J Clin Oncol"},{"issue":"10","key":"2869_CR22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983\u2013992","journal-title":"Lancet Oncol"},{"issue":"2","key":"2869_CR23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152\u2013160","journal-title":"Lancet Oncol"},{"issue":"4","key":"2869_CR24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney CJ et al (2023) Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol 24(4):323\u2013334","journal-title":"Lancet Oncol"},{"issue":"5","key":"2869_CR25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686\u2013700","journal-title":"Lancet Oncol"},{"issue":"10336","key":"2869_CR26","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K et al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 & #xd7; 2 factorial design. Lancet 399(10336):1695\u20131707","journal-title":"Lancet"},{"issue":"2","key":"2869_CR27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ajur.2017.01.002","volume":"4","author":"D Ye","year":"2017","unstructured":"Ye D et al (2017) A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-na\u00efve patients with mCRPC in China, Malaysia, Thailand and Russia. Asian J Urol 4(2):75\u201385","journal-title":"Asian J Urol"},{"issue":"12","key":"2869_CR28","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf DJ et al (2019) Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 20(12):1730\u20131739","journal-title":"Lancet Oncol"},{"issue":"5","key":"2869_CR29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","volume":"24","author":"G Attard","year":"2023","unstructured":"Attard G et al (2023) Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol 24(5):443\u2013456","journal-title":"Lancet Oncol"},{"key":"2869_CR30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euros.2022.04.016","volume":"41","author":"K Izumi","year":"2022","unstructured":"Izumi K et al (2022) Enzalutamide versus abiraterone plus prednisolone before chemotherapy for castration-resistant prostate cancer: a multicenter randomized controlled trial. Eur Urol Open Sci 41:16\u201323","journal-title":"Eur Urol Open Sci"},{"key":"2869_CR31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","volume":"158","author":"FC Maluf","year":"2021","unstructured":"Maluf FC et al (2021) A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415). Eur J Cancer 158:63\u201371","journal-title":"Eur J Cancer"},{"issue":"6","key":"2869_CR32","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s12325-022-02140-2","volume":"39","author":"Y-S Pu","year":"2022","unstructured":"Pu Y-S et al (2022) Enzalutamide in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: an Asian multiregional, randomized study. Adv Ther 39(6):2641\u20132656","journal-title":"Adv Ther"},{"issue":"2","key":"2869_CR33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","volume":"17","author":"ND Shore","year":"2016","unstructured":"Shore ND et al (2016) Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 17(2):153\u2013163","journal-title":"Lancet Oncol"},{"key":"2869_CR34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2022.04.034","volume":"171","author":"KK Ternov","year":"2022","unstructured":"Ternov KK et al (2022) Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: a randomised clinical trial (HEAT). Eur J Cancer 171:75\u201384","journal-title":"Eur J Cancer"},{"issue":"16","key":"2869_CR35","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ et al (2023) Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 389(16):1453\u20131465","journal-title":"N Engl J Med"},{"issue":"1","key":"2869_CR36","first-page":"5454727","volume":"2022","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal R et al (2022) Randomized, open-label phase 2 study of apalutamide plus androgen deprivation therapy versus apalutamide monotherapy versus androgen deprivation monotherapy in patients with biochemically recurrent prostate cancer. Prostate Cancer 2022(1):5454727","journal-title":"Prostate Cancer"},{"key":"2869_CR37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.euros.2021.09.015","volume":"34","author":"KA Autio","year":"2021","unstructured":"Autio KA et al (2021) Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy. Eur Urol Open Sci 34:70\u201378","journal-title":"Eur Urol Open Sci"},{"key":"2869_CR38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2021.06.017","volume":"157","author":"N Spetsieris","year":"2021","unstructured":"Spetsieris N et al (2021) Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na\u00efve prostate cancer. Eur J Cancer 157:259\u2013267","journal-title":"Eur J Cancer"},{"issue":"3","key":"2869_CR39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10637-014-0193-3","volume":"33","author":"DJ Crona","year":"2015","unstructured":"Crona DJ, Whang YE (2015) Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer. Invest New Drugs 33(3):751\u2013754","journal-title":"Invest New Drugs"},{"issue":"5\u20136","key":"2869_CR40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/19396368.2022.2074325","volume":"68","author":"Y Gao","year":"2022","unstructured":"Gao Y et al (2022) The effects and molecular mechanism of heat stress on spermatogenesis and the mitigation measures. Syst Biol Reprod Med 68(5\u20136):331\u2013347","journal-title":"Syst Biol Reprod Med"},{"issue":"2","key":"2869_CR41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41391-019-0195-5","volume":"23","author":"C Ryan","year":"2020","unstructured":"Ryan C, Wefel JS, Morgans AK (2020) A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer Prostatic Dis 23(2):207\u2013219","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2869_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/diseases11030103","author":"G Bushi","year":"2023","unstructured":"Bushi G et al (2023) Cardiovascular disease outcomes associated with obstructive sleep apnea in diabetics: a systematic review and meta-analysis. Diseases. https:\/\/doi.org\/10.3390\/diseases11030103","journal-title":"Diseases"},{"key":"2869_CR43","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S491130","author":"P-W Liu","year":"2025","unstructured":"Liu P-W et al (2025) A pyroptosis-related lncRNA signature for predicting prognosis, immune features and drug sensitivity in ovarian cancer. OncoTargets Ther. https:\/\/doi.org\/10.2147\/OTT.S491130","journal-title":"OncoTargets Ther"},{"issue":"6","key":"2869_CR44","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.euo.2024.02.009","volume":"7","author":"E Boerrigter","year":"2024","unstructured":"Boerrigter E et al (2024) A prospective randomised trial to determine the effect of a reduced versus standard dose of Enzalutamide on side effects in frail patients with prostate cancer. Eur Urol Oncol 7(6):1376\u20131383","journal-title":"Eur Urol Oncol"},{"key":"2869_CR45","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2022.122000","volume":"286","author":"Q Zeng","year":"2023","unstructured":"Zeng Q et al (2023) Serum raman spectroscopy combined with convolutional neural network for rapid diagnosis of HER2-positive and triple-negative breast cancer. Spectrochim Acta A Mol Biomol Spectrosc 286:122000","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"issue":"2","key":"2869_CR46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/cts.13451","volume":"16","author":"SW Huang","year":"2023","unstructured":"Huang SW et al (2023) Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: a systematic review and network meta-analysis. Clin Transl Sci 16(2):313\u2013325","journal-title":"Clin Transl Sci"},{"issue":"1","key":"2869_CR47","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102251","volume":"23","author":"A Matsukawa","year":"2025","unstructured":"Matsukawa A et al (2025) Central nervous system toxicity in prostate cancer patients treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. Clin Genitourin Cancer 23(1):102251","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"2869_CR48","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12885-022-09364-z","volume":"22","author":"A Hussain","year":"2022","unstructured":"Hussain A et al (2022) Real-world burden of adverse events for apalutamide-or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States. BMC Cancer 22(1):304","journal-title":"BMC Cancer"},{"issue":"1","key":"2869_CR49","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41598-024-52413-9","volume":"14","author":"J Zhou","year":"2024","unstructured":"Zhou J et al (2024) Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer. Sci Rep 14(1):1860","journal-title":"Sci Rep"},{"key":"2869_CR50","volume":"157","author":"D Sun","year":"2023","unstructured":"Sun D et al (2023) Disorders of cancer metabolism: the therapeutic potential of cannabinoids. Biomed Pharmacother 157:113993","journal-title":"Biomed Pharmacother"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02869-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02869-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02869-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:13:28Z","timestamp":1761848008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02869-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2869"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02869-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as there were no human participants involved in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable, as this study does not involve any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}